Angels for Change is proud to announce a major Project PROTECT milestone: our partner Fagron Sterile Services is now fully production-ready with new U.S. capacity for Sterile Water for Injection—a critical component used in countless injectable medicines.

This marks the second successful Project PROTECT collaboration with Fagron, following earlier investments that helped protect patients during the IV fluid shortage in 2024. By investing in domestic manufacturing infrastructure, we’re strengthening the resilience of the U.S. drug supply and protecting patients before shortages occur.

We don’t just talk about ending drug shortages—we’re creating solutions that build onshore readiness, strengthen supply chains, and protect patient access to lifesaving medicines.

Laura Bray and Angels for Change highlighted in the newly released white paper from the API Innovation Center, “Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain.”

Bray emphasized a clear call to action for leaders across the healthcare ecosystem to work together to solve the drug shortage crisis:

“This is not the patient’s job to solve at all… This is a supply chain failure.”

Drug shortages are making national headlines again as families search for critical medicines like leucovorin. In a recent CNN article, Angels for Change founder Laura Bray highlights how the crisis was predictable—and preventable. Through Project GOLD, Angels for Change works across the supply chain to locate scarce medications and help patients access the treatments they depend on, because no family should have to face a shortage alone.

At Angels for Change, we are proud to participate in the important work of the End Drug Shortages Alliance — serving as both an EDSA member organization and advising partner in the Drug Resiliency & Transparency Pilot.

The initial phase of the pilot demonstrated a powerful truth: when leaders come together early through trusted, neutral governance, transparency delivers real planning value.

Angels for Change today announced that the Mark Cuban Cost Plus Drug Company has completed the Preparation and Protective phases of Project PROTECT for Carboplatin Injection and Methotrexate Injection—two essential oncology medicines currently in nationwide shortage. This milestone strengthens onshore readiness and improves supply availability for patients across the United States.